{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:59:04Z","timestamp":1795089544228,"version":"4.10.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008435","name":"Penn | Perelman School of Medicine at the University of Pennsylvania | Abramson Family Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008435","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Carisma Therapeutics Inc. [Sponsored Research Agreement]"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1038\/s41587-020-0462-y","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T13:04:06Z","timestamp":1584968646000},"page":"947-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1477,"title":["Human chimeric antigen receptor macrophages for cancer immunotherapy"],"prefix":"10.1038","volume":"38","author":[{"given":"Michael","family":"Klichinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shestova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing Maggie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Zeeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Gabrusiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-9101","authenticated-orcid":false,"given":"Nicholas R.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-1735","authenticated-orcid":false,"given":"Xinhe","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-1611","authenticated-orcid":false,"given":"Kimberly","family":"Veliz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Blouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Yashiro-Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-4544","authenticated-orcid":false,"given":"Roddy S.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw S.","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-0604","authenticated-orcid":false,"given":"Dylan M.","family":"Marchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim","family":"Shestov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7778","authenticated-orcid":false,"given":"Saar","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"462_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"462_CR2","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"462_CR3","doi-asserted-by":"crossref","unstructured":"Beatty, G. L. & O\u2019Hara, M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol. Ther. 166, 30\u201339 (2016).","DOI":"10.1016\/j.pharmthera.2016.06.010"},{"key":"462_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrd.2017.84","volume":"16","author":"K Kingwell","year":"2017","unstructured":"Kingwell, K. CAR T therapies drive into new terrain. Nat. Rev. Drug Discov. 16, 301\u2013304 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"462_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00262-006-0181-3","volume":"56","author":"D Ritchie","year":"2007","unstructured":"Ritchie, D. et al. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol. Immunother. 56, 155\u2013163 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"462_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00281-013-0367-7","volume":"35","author":"SK Biswas","year":"2013","unstructured":"Biswas, S. K., Allavena, P. & Mantovani, A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35, 585\u2013600 (2013).","journal-title":"Semin. Immunopathol."},{"key":"462_CR7","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"Q Zhang","year":"2012","unstructured":"Zhang, Q. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946 (2012).","journal-title":"PLoS One"},{"key":"462_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek, C., Pont\u00e9n, F., Jirstr\u00f6m, K. & Leandersson, K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306 (2012).","journal-title":"BMC Cancer"},{"key":"462_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"462_CR10","first-page":"170","volume":"1835","author":"H-W Lee","year":"2013","unstructured":"Lee, H.-W., Choi, H.-J., Ha, S.-J., Lee, K.-T. & Kwon, Y.-G. Recruitment of monocytes\/macrophages in different tumor microenvironments. Biochim. Biophys. Acta 1835, 170\u2013179 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"462_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"462_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrd.2016.111","volume":"15","author":"C Morrison","year":"2016","unstructured":"Morrison, C. Immuno-oncologists eye up macrophage targets. Nat. Rev. Drug Discov. 15, 373\u2013374 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"462_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf, K. Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur. J. Cancer 76, 100\u2013109 (2017).","journal-title":"Eur. J. Cancer"},{"key":"462_CR14","doi-asserted-by":"crossref","unstructured":"Weiskopf, K. & Weissman, I. L. Macrophages are critical effectors of antibodies therapies for cancer. MAbs 7, 303\u2013310 (2015).","DOI":"10.1080\/19420862.2015.1011450"},{"key":"462_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf, K. et al. Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88\u201391 (2013).","journal-title":"Science"},{"key":"462_CR16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/JLB.2MIR0917-354R","volume":"103","author":"A Roghanian","year":"2018","unstructured":"Roghanian, A., Stopforth, R. J., Dahal, L. N. & Cragg, M. S. New revelations from an old receptor: immunoregulatory functions of the inhibitory Fc gamma receptor, Fc\u03b3RIIB (CD32B). J. Leukoc. Biol. 103, 1077\u20131088 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"462_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cmi.12580","volume":"18","author":"L Franken","year":"2016","unstructured":"Franken, L., Schiwon, M. & Kurts, C. Macrophages: sentinels and regulators of the immune system. Cell. Microbiol. 18, 475\u2013487 (2016).","journal-title":"Cell. Microbiol."},{"key":"462_CR18","doi-asserted-by":"publisher","first-page":"e40311","DOI":"10.1371\/journal.pone.0040311","volume":"7","author":"MM Barrio","year":"2012","unstructured":"Barrio, M. M. et al. Human macrophages and dendritic cells can equally present MART-1 Antigen to CD8+ T cells after phagocytosis of gamma-irradiated melanoma cells. PLoS One 7, e40311 (2012).","journal-title":"PLoS One"},{"key":"462_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04985-0","volume":"9","author":"T-L Tang-Huau","year":"2018","unstructured":"Tang-Huau, T.-L. et al. Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway. Nat. Commun. 9, 2570 (2018).","journal-title":"Nat. Commun."},{"key":"462_CR20","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.4049\/jimmunol.181.9.5829","volume":"181","author":"DA Hume","year":"2008","unstructured":"Hume, D. A. Macrophages as APC and the dendritic cell myth. J. Immunol. 181, 5829\u20135835 (2008).","journal-title":"J. Immunol."},{"key":"462_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jlb.64.4.419","volume":"64","author":"R Andreesen","year":"1998","unstructured":"Andreesen, R., Hennemann, B. & Krause, S. W. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J. Leukoc. Biol. 64, 419\u2013426 (1998).","journal-title":"J. Leukoc. Biol."},{"key":"462_CR22","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/S0022-5347(05)64148-1","volume":"168","author":"N Thiounn","year":"2002","unstructured":"Thiounn, N. et al. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J. Urol. 168, 2373\u20132376 (2002).","journal-title":"J. Urol."},{"key":"462_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-54","volume":"8","author":"M Burger","year":"2010","unstructured":"Burger, M. et al. The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial. J. Transl. Med. 8, 54 (2010).","journal-title":"J. Transl. Med."},{"key":"462_CR24","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","volume":"9","author":"A Gaggar","year":"2003","unstructured":"Gaggar, A., Shayakhmetov, D. M. & Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408\u20131412 (2003).","journal-title":"Nat. Med."},{"key":"462_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jgm.543","volume":"6","author":"M Nilsson","year":"2004","unstructured":"Nilsson, M. et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J. Gene Med. 6, 631\u2013641 (2004).","journal-title":"J. Gene Med."},{"key":"462_CR26","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.4049\/jimmunol.178.8.5245","volume":"178","author":"AJ Fleetwood","year":"2007","unstructured":"Fleetwood, A. J., Lawrence, T., Hamilton, J. A. & Cook, A. D. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol. 178, 5245\u20135252 (2007).","journal-title":"J. Immunol."},{"key":"462_CR27","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","volume":"24","author":"M Wunderlich","year":"2010","unstructured":"Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785\u20131788 (2010).","journal-title":"Leukemia"},{"key":"462_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958\u2013969 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"462_CR29","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1128\/JVI.02702-13","volume":"88","author":"E Lam","year":"2014","unstructured":"Lam, E., Stein, S. & Falck-Pedersen, E. Adenovirus detection by the cGAS\/STING\/TBK1 DNA sensing cascade. J. Virol. 88, 974\u2013981 (2014).","journal-title":"J. Virol."},{"key":"462_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature06664","volume":"452","author":"DA Muruve","year":"2008","unstructured":"Muruve, D. A. et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103\u2013107 (2008).","journal-title":"Nature"},{"key":"462_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/cr.2015.68","volume":"25","author":"B Kelly","year":"2015","unstructured":"Kelly, B. & O\u2019Neill, L. A. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 25, 771\u2013784 (2015).","journal-title":"Cell Res."},{"key":"462_CR32","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"462_CR33","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343\u20132354 (2014).","journal-title":"Blood"},{"key":"462_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/gt.2012.61","volume":"20","author":"S Bobadilla","year":"2013","unstructured":"Bobadilla, S., Sunseri, N. & Landau, N. R. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Ther. 20, 514\u2013520 (2013).","journal-title":"Gene Ther."},{"key":"462_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"462_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914\u2013921 (2015).","journal-title":"Nat. Med."},{"key":"462_CR37","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-020-0462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-020-0462-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-020-0462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:23:11Z","timestamp":1738599791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-020-0462-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1038\/s41587-020-0462-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737604755.793574259","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.737604755.793573014","asserted-by":"object"}]},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"31 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. and S.G. are scientific co-founders and Scientific Advisory Board members and hold equity in Carisma Therapeutics. C.J. is a member of the Scientific Advisory Board of Carisma Therapeutics. M.K., S.G. and C.J. are inventors on intellectual property related to this work. S.G. has received research funding from Carisma Therapeutics. A.B., M.Z., M.S., K.G., N.A., Y.O. and M.K. are employees of Carisma Therapeutics. Carisma Therapeutics is a company pursuing the commercial development of this technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}